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Objective: The present study reviews predictive models used to improve prediction of
psychosis onset in individuals at clinical high risk for psychosis (CHR), using clinical,
biological, neurocognitive, environmental, and combinations of predictors.
Methods: A systematic literature search on PubMed was carried out (from 1998 through
2019) to find all studies that developed or validated a model predicting the transition to
psychosis in CHR subjects.
Results: We found 1,406 records. Thirty-eight of them met the inclusion criteria; 11
studies using clinical predictive models, seven studies using biological models, five studies
using neurocognitive models, five studies using environmental models, and 18 studies
using combinations of predictive models across different domains. While the highest
positive predictive value (PPV) in clinical, biological, neurocognitive, and combined
predictive models were relatively high (all above 83), the highest PPV across
environmental predictive models was modest (63%). Moreover, none of the combined
models showed a superiority when compared with more parsimonious models (using only
neurocognitive, clinical, biological, or environmental factors).
Conclusions: The use of predictive models may allow high prognostic accuracy for
psychosis prediction in CHR individuals. However, only ten studies had performed an
internal validation of their models. Among the models with the highest PPVs, only the
biological and neurocognitive but not the combined models underwent validation. Further
validation of predicted models is needed to ensure external validity.
Keywords: clinical high risk for psychosis (CHR), attenuated psychotic symptoms (APS), brief and limited
intermittent psychotic symptoms (BLIPS), genetic risk and deterioration syndrome (GRD), predictive modelINTRODUCTION
Psychotic disorders are some of the most serious mental disorders considering the individual and
the social impact (1, 2). They represented the 11th cause of disability in the world in 2013 (3). The
delay between the diagnosis and the treatment ranges from 1 to 3 years (4) and results in worsening
clinical outcomes (5). Therefore, the clinical focus has increasingly shifted to the early detection and
treatment with the aim to either attenuate, postpone and globally avoid the transition to psychosis
(6), or enhance clinical and functional outcomes of psychosis over time (7, 8). Psychosis does notg March 2020 | Volume 11 | Article 2231
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develops over time: often the first manifestations already take
place in adolescents (9, 10). For most of the patients suffering
from schizophrenia and psychotic disorders, the onset of the
disease is anticipated by different symptoms: slight changes in
belief, thought, and perception that represent mild forms of
delusions, formal thought disorder, and hallucinations,
respectively (11).
The clinical staging model has been created to catch these
progressive changes, with progressively increasing levels of
severi ty over t ime (12, 13) . This model descr ibes
psychopathology in a continuum of different subsequent
stages. It comprises five different stages, from stage 0 to stage
4, starting from the lowest level of increased risk of mental illness
to progressively higher stages of severity, leading to separated but
overlapping pathologies at the highest levels (14, 15). Stage 0
includes subjects at increased risk without any kind of
symptoms; stage 1 refers to individuals at clinical high risk for
psychosis (CHR); stage 2 coincides with the acute phase or crisis,
featured by full-blown psychotic symptoms (the full-threshold
first episode psychosis), after which an early recovery phase or
post- acute phase in the 6–12 months after the onset of the
disease occurs; stage 3 encompasses individuals with either
persistent illness or recurrent episodes after the first one (12,
13, 16) and stage 4 holds subjects with chronic disease.
This psychopathological model allows to stage this pathology
so that different types of interventions, depending on the stage of
illness, can be developed. The psychopathology would be more
susceptible to intervention strategies in the first phases of the
disease and more crystallized and resistant to therapies in the last
phases (15).
The CHR criteria include: attenuated psychotic symptoms
(APS), representing mild positive symptoms; brief and limited
intermittent psychotic symptoms (BLIPS), characterized by
transient, non-serious psychotic symptoms lasting part of the
day, and lasted for a maximum period of one week after which
spontaneously went to remission; and genetic risk and
deterioration syndrome (GRD), including patients with family
history of psychosis or schizotypal personality disorder, with
additional decline in functioning (17).
Frequently, research in the area of psychiatry has as principal
focus the transition from CHR to First Episode Psychosis. Help-
seeking subjects meeting CHR criteria, regardless of the scale
used, have an increased risk to develop psychotic disorders (18),
within a period of time that can be considered quite short.
According to a meta-analysis storing data from 27 studies
including a number of 2,502 patients, 18% of them developed
First Episode Psychosis at by 6 months, 22% by 1 year, 29% by 2
years, and 36% by 3 years from initial assessment (19), with
about 73% of these developing a schizophrenia spectrum
disorder (20).
Overall, compared to the general population, CHR subjects
have a 2-year relative risk (RR) to develop psychosis of 460%
as compared to general population (29%/0.063%) (21).
However, extracting from the overall high-risk entity, itsFrontiers in Psychiatry | www.frontiersin.org 2three principal subgroups, patients with BLIPS were at
greater risk for developing psychosis (39% vs 19% after 24
months), than patients in the APS and GRD subgroups (22),
while the GRD subgroup shows only a slight transition risks of
5% after three years of follow-up (22).
Since most of the studies conducted a follow-up period of not
more than 3 years, after this period the transition rate to
psychosis is not completely clear. However, most conversions
occur during the first year following the evaluation and the
conversion rate decreases significantly thereafter, suggesting that
the CHR criteria are sensitive to an imminent risk of the onset of
full psychosis (23). However, the CHR criteria alone seem to be
insufficient in predicting the imminence of the first episode
psychosis, given that from 2/3 to 4/5 cases identified through
these instruments do not turn into psychosis within a period of 2
years (24). Thus, the aim is to propose a prognostic model that
more effectively picks out those individuals who are more likely
to switch from ultra-high risk to a first-episode psychosis (FEP)
within a given period of time, to adapt treatments to what
subjects really need.
Nevertheless, there is not a model of prediction of the
transition to psychosis that has been utilized in clinical
practice. One explanation can be that psychotic disorders are
heterogeneous in phenomenology, pathophysiology, and
etiology (25): it means that CHR samples are composed of
different and largely heterogeneous subgroups (26). Another
reason can be found in the poor quality of the statistical
methods used in the studies involved in developing a transition
model from CHR stage to full-blown psychosis. A recent review
on 91 studies highlighted several shortcomings of this kind of
research: poor methods and reporting, no internal or external
cross-validation, small sample sizes, and strategies to create these
models not well done. Therefore, most of these models probably
have overoptimistic and not realistic predictive accuracy (27).
The present study reviews models predicting transition to
psychosis, developed to enhance prediction of illness onset in
CHR subjects, extending results of a previous study of prognostic
accuracy parameters of predictive modeling studies using
clinical, biological, neurocognitive, environmental, and
combinations of predictors (28).METHODS
Literature Search
On January 31, 2019, an electronic search on PubMed was
carried out (from 1998 through 2019), using the following
search terms: “at risk mental state,” “psychosis risk,”
“prodrome,” “prodromal psychosis,” “high risk,” “clinical high
risk psychosis”, “attenuated psychotic symptoms”, “APS”, “brief
and limited intermittent psychotic symptoms”, “BLIPS”, “brief
intermittent psychosis syndrome”, “BIPS”, “genetic risk and
deterioration syndrome”, “GRD”, “psychosis prediction,”
“psychosis onset,” “predictive model”. The research was
restricted to those articles published from 1998 onward,March 2020 | Volume 11 | Article 223
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subjects meeting validated CHR criteria have been
published (29).
This qualitative review was executed according to the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) standard, including evaluation of bias
(confounding, overlapping data, publication bias) (30).
(Figure 1).
Studies were selected in a two-step procedure. First of all, all
references retrieved from the databases were screened based on
their titles and abstracts. Subsequently, the articles that were
potentially eligible were further evaluated based on their full
texts. All references within the included studies and those of
any previous pertinent reviews were carefully reviewed to
identify additional relevant studies. Discrepancies were
resolved by mutual discussions. Consensus was then
obtained, resulting in a final set of articles that have been
reviewed and summarized.Frontiers in Psychiatry | www.frontiersin.org 3Inclusion/Exclusion Criteria
As depicted in Figure 1, these are the inclusion criteria for the
studies in the present review: (a) original articles, to be published
in English; (b) presence of CHR subjects [i.e., APS or GRD or
BLIPS or brief intermittent psychosis syndrome (BIPS)]
according to international standard criteria (6); (c) inclusion of
clinical, biological, neurocognitive, environmental, or
combinations of predictors to separate CHR individuals who
later developed psychosis from those who did not; (d) inclusion
of rigorous predictive models, algorithms, or learning systems
that predicted later transition to psychosis from variables
obtained at baseline, like regression (logistic, Cox proportional
hazard model, least absolute shrinkage, and selection operator),
support vector machines, or greedy algorithms (31–34).
The following were the exclusion criteria: (a) abstracts, pilot
datasets, reviews, articles not written in English; (b) not rigorous
statistic methods (i.e., use of mean differences or chi square
tests); (c) articles with overlapping datasets using the sameFIGURE 1 | PRISMA flow chart.March 2020 | Volume 11 | Article 223
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using the same population sample, we have chosen the studies
reporting the largest sample and most recent data set.
Recorded Variables
Two investigators (CM, NB) independently realized the
extrapolation of data. Several variables have been extracted
from the evaluated articles: author, year of publication,
demographic characteristics of the CHR sample, predictor
domain (clinical, biological, neurocognitive, environmental,
combinations), cut-off of predictive variables, type of
validation, diagnostic instrument used to define CHR group,
administration of antipsychotics, follow-up time, predictive
model, and prognostic accuracy data (sensibility SE, specificity
SP, positive predictive value PPV, negative predictive value
NPV). Moreover, we checked the missing data with all the
corresponding authors to record all the information we needed.RESULTS
Selection of Studies
Search
Figure 1 describes the details of what has been searched in
literature and the reasons why some articles were excluded. The
electronic and manual search described in the previous section
provided 1,406 records.
Thirty-eight of these studies met the inclusion criteria: 11
studies made use of clinical predictive models, seven studies used
biological models, five studies made use of neurocognitive
models, five studies used environmental models, and 18 studies
made use of combinations of predictive models across different
domains. The results are schematically described in Table 1.
For all these studies, validation was evaluated. Some models
have internal validation, that means test model in new data,
random from underlying population. Other studies have external
validation, that means test model in new data, different from
development population. Some models have apparent validation,
that gives an optimistic estimate of model performance. Some
studies have a cross-validation: it means to test the model's ability
to predict new data that was not used in estimating it, in order to
flag problems like overfitting or selection bias (6) and to give an
insight on how the model will generalize to an independent
dataset. However, some models do not show any validation.
Clinical Predictive Models
The 11 studies that have tested the clinical predictive models are
described in Tables 1 and 2. The clinical parameters included
specific positive [odd belief: (35); auditory hallucinations: (35,
45); unusual thought content: (36); illogical thinking: (39);
suspiciousness: (36, 42, 43); bizarre thinking: (44); delusions:
(45) ; formal thought disorders : (45) ; disorganized
communication: (40, 41); positive symptoms: (41)], negative
[anhedonia/asociality: (35, 43); blunted affect: (35); alogia:Frontiers in Psychiatry | www.frontiersin.org 4(43)] and basic symptoms (41), social and global functioning
(35–37, 44), and the Strauss and Carpenter Prognostic Scale
(SCPS) (38). In details, we found that the best clinical predictors
recognized were schizotypal personality characteristics (35),
formal thought disorders (39), specific items of the SCPS
assessing quality of useful work and social relations, positive
symptoms and subjective distress (38), disorganized
communication (particularly, subthreshold thought disorder)
both at baseline and as a trajectory of high persistent
disorganized communication (40), and early adolescent social
dysfunction (43), with baseline prodromal symptoms of
disorganized communication, social anhedonia, suspiciousness,
and diminished ideational richness that mediate the association
with transition to psychosis. We found that several studies
presented an increased predictive power when more variables
were evaluated together. Particularly, a prediction model was
developed and included positive symptoms, bizarre thinking,
sleep disturbances, a schizotypal disorder, level of functioning in
the past year, and years of education (44). Another study, using
the median score of the global assessment of functioning scale
(GAF) and the QLS scale, identified a “high” and “low” group
(comprising of subjects functioning above or below median at
both baseline and follow-up) and a “deterioration” group and
“improving” group; Chi-square analyses showed that the low and
deteriorating functioning groups were the most likely to develop
FEP (45). Otherwise, Cannon et colleagues (36) found that five
features contributed uniquely to the prediction of psychosis: a
genetic risk for schizophrenia with recent deterioration in
functioning, higher levels of unusual thought content, higher
levels of suspicion/paranoia, greater social impairment, and a
history of substance abuse. Predictive power was increased when
prediction algorithms combining two or three of these variables
were generated. Other studies have highlighted several different
factors associated with transition to psychosis. A study (37) has
identified five factors: year of entry into the clinic, duration of
symptoms before clinic entry, baseline functioning, negative
symptoms, and disorders of thought content. Another study
(41) has recognized low IQ, the severity of attenuated positive
symptoms, and particularly disorganized symptoms that were
identified as highly predictive of functional outcome. A study
(42) has identified, as the best transition predictors, selected APS
(suspiciousness), negative symptoms (anhedonia/asociality), and
cognitive deficits (reduced speed of information processing).
The highest PPV of 88.3% was obtained using a model that
included measures of delusions, hallucinations or formal thought
disorder (45). This model reached a SE of 97.3%, SP of 86.5%, and
NPV of 96.8%. The worst PPV (24%) was produced by combining
the following items of the SCPS for transition to a first psychotic
episode in subjects clinically at high risk (CHR) of psychosis: most
usual quality of useful work in the past year, quality of social
relations, presence of thought disorder, delusions or hallucinations
in the past year, and reported severity of subjective distress in past
month, a predictive model that revealed an SE value of 76%, SP of
57%, and NPV of 93% (38).
Validation was not obtained in any clinical predictive model.March 2020 | Volume 11 | Article 223
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Seven studies have evaluated the prognostic accuracy of
biological predictive models (Table 2). These studies have
taken into consideration the MRI based biomarkers (50, 52),
multivariate neuroanatomical pattern (51), electrophysiological
indicators [quantitative EEG: (46, 49); ERP: event-related
potentials: (48)], and blood analyses (47). In details, two
studies took into consideration quantitative EEG (46, 49). Van
Tricht and colleagues (46) determined quantitative EEG (QEEG)
spectral power and alpha peak frequencies (APF), founding that
power in theta and delta ranges and occipital–parietal APF
contribute to the short-term prediction of psychosis and enable
a further stratification of risk in CHR samples. Ramyead et al.Frontiers in Psychiatry | www.frontiersin.org 5(49) assessed the individualized prediction of psychosis by
detecting specific patterns of beta and gamma oscillations
using machine-learning algorithms, determining that transition
to psychosis could be predicted from current-source density
(CSD). This study found that left superior temporal gyrus, the
left inferior parietal lobule, and the precuneus most strongly
contributed to the prediction of psychosis, suggesting that CSD
measurements extracted from clinical resting state EEG can be
useful to improve the prediction to psychosis. A study (47) took
into consideration blood biomarkers, measuring expression of
plasma analytes reflecting inflammation, oxidative stress,
hormones, and metabolism. A “greedy algorithm” selected
analytes that best distinguished individuals with clinical high-TABLE 1 | Articles Reporting Predictive Models of Transition to Psychotic Disorder in CHR Subjects.
Articles Type of CHR diagnostic instrument
used
Sample of the CHR subjects (NT/
T)
Antipsychotics (patients
treated)
Follow-up
(months)
Mason et al. (35) APSS, BPRS, SAPS, SANS 37/37 No 26
Cannon et al. (36) SIPS 209/82 Yes 30
Nelson et al. (37) CAARMS, BPRS 197/114 No 60
Nieman et al. (38) SIPS, BSABS-P 207/37 Yes 18
Bearden et al. (39) SIPS 33/21 Yes 12
DeVylder et al. (40) SIPS 74/26 Yes 30
Ziermans et al. (41) SIPS, BSABS-P 33/10 Yes 72
Riecher-Rössler et al.
(42)
BSIP, BPRS, SANS 32/21 No 64
Tarbox et al. (43) SIPS 192/78 n/a 30
Ruhrmann et al. (44) SIPS, BSABS-P 146/37 Yes 18
Velthorst et al. (45) SIPS 119/28 No 24
van Tricht et al. (46) SIPS 91/22 Yes 18
Perkins et al. (47) SIPS 40/32 Yes 24
Van Tricht et al. (48) SIPS, PANSS, PAS 43/18 16* 36
Ramyead et al. (49) BSIP 35/18 No 36
Koutsouleris et al. (50) BSIP, BPRS 21/16 4 84
Koutsouleris et al. (51) BSABS 18/15 No 18
Koutsouleris et al. (52) BPRS, SANS, PANSS 33/33 No 52
Hoffman et al. (53) SIPS 19/9 No 24
Koutsouleris et al. (54) CAARMS, BSABS-P 20/15 No 48
Pukrop et al. (55) SIPS, BSABS-P 39/44 No 36
Fusar-Poli et al. (56) CAARMS 129/23 Yes 24
Dragt et al. (57) SIPS and BSABS-P 53/19 Yes 36
Buchy et al. (58) SIPS 141/29 No 48
Nieman et al. (59) SIPS, BSABS-P 43/18 Yes 36
Lencez et al. (60) SIPS 21/12 No 32
Cornblatt et al. (61) SIPS 77/15 Yes 36
Michel et al. (62) SIPS, SPI-A 53/44 Yes 24
Chan et al. (63) CAARMS 58/18 No 24
Corcoran et al. (64) SIPS, SOPS 42/7 n/a 24
Gschwandtner et al. (65) BSIP, BPRS 30/12 No 72
Mittal. et al. (66) SIPS 66/24 13 24
Rüsch et al. (67) SIPS 159/13 33 12
Thompson et al. (68) CAARMS 63/41 No 28
Zimmermann et al. (69) BPRS, SANS 15/13 4 48
Ruhrmann et al. (44) BSABS-P, SIPS 208/37 55 18
Yung et al. (70) CASH, BPRS 68/36 No 12
Yung et al. (71) CASH, BPRS 29/20 No 12March 2020 | VolAPSS, the assessment of prodromal and schizotypal symptoms; BPRS, Brief Psychiatric Rating Scale; BSABS-P, The Bonn Scale for the assessment of basic symptoms- prediction list;
BSIP, Basel Screening Instrument for Psychosis; CAARMS, comprehensive assessment of at risk mental states; CASH, comprehensive assessment of symptoms and history; CHR,
clinical high risk; ERIraos, early recognition inventory based on the retrospective assessment of the onset of schizophrenia; HR, high risk; n/a not available; NT, nontransition; PANSS,
Positive and Negative Symptoms Scale; PAS, premorbid assessment scale; PSE, present state examination; SANS; Scale for Assessment of Negative Symptoms; SAPS, Scale for
Assessment of Positive Symptoms; SD, standard deviation; SIPS, structured interview for prodromal syndromes; SOPS, Scale of Prodromal Symptoms; SPI-A, Schizophrenia Proneness
Instrument, Adult version; T:transition.aData are shown for the CHR subjects with a known outcome (n=183). The total group included 245 subjects.
*16 subjects treated: 9 of them nontransition and 7 transition to psychosis.ume 11 | Article 223
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Articles Predictor area Predictive
model
Validation Predictive variables (Cut-off and/or AUC) SE
(%)
SP
(%)
PPV
(%)
NPV
(%)
Mason et al.
(35)
Clinical Logistic
regression
No Odd belief (SPD ≥ 1), marked impairment in role functioning (APSS ≥
mild), auditory hallucinations (SAPS ≥ 2), anhedonia/asociality (SANS ≥ 2),
blunted affect (APSS ≥ mild)
84 86 86 84
Cannon
et al. (36)
Clinical Cox
proportional
hazard model
No Unusual thought content (SIPS > 3) 56 62 48 /
Suspicion/paranoia (SIPS > 2) 79 37 43 /
Social functioning (SIPS < 7) 80 43 46 /
Psychosis in first-degree relatives with functional decline (GAF and SIPS) 66 59 52 /
Nelson et al.
(37)
Clinical Cox
proportional
hazard model
No Global functioning (GAF < 44), duration symptoms (CAARMS > 738 d) 45 88 72 69
Nieman
et al. (38)
Clinical Cox
proportional
hazard model
No SCPS < 49 76 57 24 93
Bearden
et al. (39)
Clinical Logistic
regression
No Illogical thinking score (K-FTDS) 69 71 / /
DeVylder
et al. (40)
Clinical Cox
proportional
hazard model
No Disorganized communication (SIPS > 2, AUC in the 2 through 4 range:
0.64)
81 38 33 85
Disorganized communication (SIPS > 3, AUC in the 2 through 4 range:
0.64)b
62 62 36 82
Disorganized communication score (SIPS > 4, AUC in the 2 through 4
range: 0.64)
31 81 36 77
Ziermans
et al. (41)
Clinical Logistic
regression
No Positive symptoms (SIPS > 11.5, AUC: 0.80) 40 85 44 /
Cognitive deficits ≥ 19 (BSABS-P ≥ 19, AUC: 0.79) 67 87 60 91
Riecher-
Rössler
et al. (42)
Clinical Logistic
regression
No Suspiciousness (BPRS:0.41, AUC: 0.72) 70 72 61 79
Tarbox et al.
(43)
Clinical Cox
proportional
hazard model
No Alogia, anhedonia-asociality (SANS:0.33, AUC: 0.78) 79 68 / /
Suspiciousness (SIPS > 3) 53 76 51 75
Ruhrmann
et al. (44)
Clinical Cox
proportional
hazard model
No Disorganized communication (SIPS > 1) 72 46 40 76
Social anhedonia (SIPS >2) 69 58 46 80
Positive symptoms (SIPS>16), bizarre thinking (SIPS > 2), schizotypal
personality disorder (SIPS), highest functioning score in the past year
(GAF-M score), sleep disturbances (SIPS>2), years of education, AUC:
0.81
42 98 83 87
Velthorst
et al. (45)
Clinical Logistic
regression
Apparent PANSS, with a score of 4 or more on delusions, hallucinations or formal
thought disorder'; having a score of 6 on any of the items of the SIPS-
Positive Symptoms subscales for more than 7 d. LCFA to the 19 items of
the SIPS.
97.3 86.5 88.3 96.8
Van Tricht
et al. (46)
Biological Cox
proportional
hazard model
No Quantitative EEG: occipital-parietal individual alpha peak frequency, frontal
delta and theta power.
46 87 56 87
Perkins et al.
(47)
Biological Greedy
algorithm
Internal Blood biomarker: interleukin-1B, GH, KIT ligand, interleukin-8, matrix
metalloproteinase-7, interleukin-7, resistin, chemokine [c-c motif] ligand8,
immunoglobulin E, coagulation factor VII, TSH, malondialdehyde-modified
low-density lipoprotein, apolipoproteinD, uromodulin and cortisol (AUC:
0.88)
60 90 72 84
Van Tricht
et al. (48)
Biological Cox
proportional
hazard model
No ERP: P300 (Amplitude < 14.7 microvolt) 83 79 / /
Ramyead et al.
(49)
Biological LASSO Internal Quantitative EEG: lagged phase synchronization, current-source density
(AUC: 0.78)
58 83 / /
Koutsouleris
et al. (50)
Biological Binary SVM
with radial
Internal with
nested
repeated 10-
MRI-based biomarkers (The neuroanatomical decision functions
underlying these results particularly involved the prefrontal perisylvian and
subcortical brain structures)
81.0 87.5 77.8 89.5
(Continued)Frontiers in Psychiatry | www.frontiersin.org March 20206 | Volume 11 | Article 223
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Articles Predictor area Predictive
model
Validation Predictive variables (Cut-off and/or AUC) SE
(%)
SP
(%)
PPV
(%)
NPV
(%)
basis
function
fold cross-
validation
Koutsouleris
et al. (51)
Biological Binary SVM
with radial
basis
function
Internal with
5-fold cross-
validation
Multivariate neuroanatomical pattern classification performed on the
structural magnetic resonance imaging data
83 80 83 80
Koutsouleris
et al. (52)
Biological SVM Internal Gray matter volume reduction (dorsomedial, ventromedial, and
orbitofrontal areas extending to the cingulate and right intra- and
perisylvian structures
76 85 83 78
Hoffman et al.
(53)
Neurocognitive Cox
proportional
hazard model
No Length of speech illusion (babble task ≥ 4) 89 90 80 94
Koutsouleris
et al. (54)
Neurocognitive SVM Internal Verbal and executive functioning (MWT-B, DST, TMT-B, RAVLT-DR, and
RAVLT-Ret)
75 80 83 71
Riecher-
Rössler et al.
(43)
Neurocognitive Logistic
regression
No Verbal IQ and attention (MWT/TAP Go/NoGo false alarm: 0.38, AUC:
0.62)
80 59 57 83
Pukrop et al.
(55)
Neurocognitive Logistic
regression
No Verbal memory–delayed recall (Auditory Verbal Learning Test), verbal IQ
(Multiple Choice Vocabulary Test), verbal memory–immediate recall
(Auditory Verbal Learning Test) and processing speed (DST)
75 79 80 74
Ziermans et al.
(41)
Neurocognitive Logistic
regression
No IQ (Wechsler Intelligence Scales < 86.5, AUC: 0.77) 40 97 80 84
Fusar-Poli
et al. (56)
Environmental Log-rank test No Unemployment (“yes/no” assessed with unstandardized questionnaire) 57 61 20 89
Dragt et al.
(57)
Environmental Cox
proportional
hazard model
No Urbanicity (BDF, ≤100 000 inhabitants), impaired 63 88 63 88
social-sexual aspects, age 12–15 (PAS), impaired
social-personal adjustment, general (PAS)
Tarbox et al.
(43)
Environmental Cox
proportional
hazard
No Early adolescent social maladjustment (PAS > 2) 50 71 46 72
Buchy et al.
(58)
Environmental Cox
proportional
hazard
No Alcohol use (“yes/no” AUS/DUS) 69 81 26 90
Cannon et al.
(36)
Environmental Cox
proportional
hazard model
No Abuse of alcohol, hypnotics, cannabis, amphetamines, opiates, cocaine,
hallucinogens (“yes/no” as assessed by the Structured Clinical Interview
for DSM-IV or the Schedule for Affective Disorders and Schizophrenia for
School-Age Children)
29 83 43 /
Ziermans et al.
(41)
Combination Logistic
regression
No Positive symptoms (SIPS > 11.5) and IQ (Wechsler Intelligence Scales ≤
86.5) (AUC: 0.82)
50 91 63 86
Riecher-
Rössler et al.
(42)
Combination Logistic
regression
Internal Suspiciousness (BPRS), anhedonia-asociality (SANS) and attention (TAP
Go/NoGo false alarm) (cut-off: 0.41, AUC: 0.87)
83 79 71 86
Nieman et al.
(59)
Combination Cox
proportional
hazard
Internal P300 amplitude (ERP), social-personal adjustment 78 88 74 90
model (PAS) (AUC: 0.86)
Lencz et al.
(60)
Combination Logistic
regression
No Verbal memory (Wechsler Memory Scale) and positive symptoms (SIPS)
(AUC: 0.43)
82 79 69 88
Tarbox et al.
(43)
Combination Cox
proportional
hazard model
No Early adolescent social maladjustment (PAS > 2), suspiciousness (SIPS >
3)
28 92 59 70
Early adolescent social maladjustment (PAS > 2), disorganized
communication (SIPS > 1)
42 82 51 72
Early adolescent social maladjustment (PAS > 2), social anhedonia (SIPS
> 2)
43 78 49 72
Early adolescent social maladjustment (PAS > 2), ideational richness
(SIPS > 0)
32 85 50 70
Cornblatt et al.
(61)
Combination Cox
proportional
hazard model
No Disorganized communication (SIPS > 2), suspiciousness (SIPS = 5),
verbal memory deficit 2 SD below normal, declining social functioning
(Global Functioning: Social scale) (AUC: 0.92)
60 97 82 93
(Continued)Frontiers in Psychiatry | www.frontiersin.org March 20207 | Volume 11 | Article 223
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15 analytes (selected from 117). These results support the
hypothesis that inflammation, oxidative stress, and
dysregulation of hypothalamic-pituitary axes may be
prominent in the earliest stages of psychosis and could lead to
develop a multiplex blood assay with a potential for high clinical
utility. A study (48) analyzed abnormalities on neuroimaging
and neuropsychological examinations before the onset of a firstFrontiers in Psychiatry | www.frontiersin.org 8psychotic episode, founding that reduced P3 amplitudes (a scalp-
recorded late ERP, occurring approximately 300 ms after an
attended unusual or task-relevant stimulus.) were identified as
the best predictor for subsequent psychosis in the UHR group.
The P3 reduction was related to increased social anhedonia and
withdrawal and a lower global assessment of social functioning
and social personal adjustment. Different studies (50, 52)
concentrated their efforts in individuate MRI biomarkers: theTABLE 2 | Continued
Articles Predictor area Predictive
model
Validation Predictive variables (Cut-off and/or AUC) SE
(%)
SP
(%)
PPV
(%)
NPV
(%)
Cannon et al.
(36)
Combination Cox
proportional
hazard model
No Psychosis in first-degree relatives with functional decline (SIPS and GAF),
unusual thought content (SIPS > 3), social functioning (SIPS < 7)
30 90 81 /
Michel et al.
(62)
Combination Cox
proportional
hazard
Internal UHR criteria (SIPS), DST deficit t-score < 40, COGDIS criteria (BSABS-P) 57 66 58 65
Chan et al. (63) Combination LASSO 10-fold cross
validation
22-Analyte panel, CAARMS-positive subscale (AUC:0.90) 89 79 57 96
Corcoran et al.
(64)
Combination Logistic
regression
Apparent Facial emotion discrimination (EMODIFF), Facial emotion recognition
(ER40), Negative symptoms (AUC:0.99)
86 98 86 98
Gschwandtner
et al. (65)
Combination Logistic
regression
model
No EEG and general psychopathology (SANS and BPRS) (AUC=0.81) 82 73 / /
Mittal et al. (66) Combination Linear
discriminant
analysis
Internal with
leave one
out cross-
validation
Movement abnormalities (Dyskinesia Identification System: Condensed
User), functional domains (WAIS-III, WISC-III), Neurocognition (FSIQ,
vocabulary, matrix reasoning, block design, Logical memory I, Logical
Memory II
76.0 60 86.3 43
Rusch et al.
(67)
Combination Logistic
regression
and cox
proportional
hazard model
Apparent Positive and Negative symptoms (PANSS), perceived stigma-related harm
(validated 8-item self-report measure based on Lazarus and Folkman's
(1984) conceptualization of stress appraisal processes; using the median
of as a cut off)
58 98 / /
Thompson
et al. (68)
Combination Cox
proportional
hazard model
Apparent Genetic risk with functional decline; high unusual thought content score
(>3 on the SIPS); high suspicion/paranoia score (>2 on the SIPS); low
social functioning (<7 on the Social Functioning Scale) and history of
substance abuse.
37.3 87.2 65.4 68.2
Zimmermann
et al. (69)
Combination Logistic
regression
Apparent Negative symptom scale (SANS) and EEG spectral data (EEG power in
seven bands: delta, theta, alpha1, alpha2, beta1, beta2, beta3)
92 87 86 93
Ruhrmann
et al. (44)
Combination Cox
proportion
hazard model
Apparent SIPS-Positive score, bizarre thinking, sleep disturbances, schizotypal
personality disorder (according to SIPS) highest GAF-M score in the past
year, and years of education (AUC: 80.8)
41.7 97.9 83.3 87.0
Yung et al. (70) Combination Cox
proportional
hazard model
Apparent Belonging to both the Trait and Attenuated Groups, Duration>5 years,
SANS attention>2, GAF<40
60.0 92.6 80.8 81.8
Yung et al. (71) Combination Cox
proportional
hazard
model
Apparent Duration of symptoms > 900 d, GAF
score < 51, BPRS total > 15, BPRS
psychotic subscale > 2, SANS attention
score > 1 and HRSD > 18
86 91 80 94March 2020 | Volume 11 | ArticCAARMS, Comprehensive Assessment of At-Risk Mental State; LCFA, Latent Class Factor Analysis; NPV, negative predictive value; PPV, positive predictive value; SE, sensibility; SP,
specificity.
Adapted by Schmidt et al. (28).
APSS, the assessment of prodromal and schizotypal symptoms; AUC, area under the curve; AUS/DUS, The Alcohol and Drug Use Scale; BDF, basic data form; BPRS,
Brief Psychiatric Rating Scale; BSABS-P, The Bonn Scale for the assessment of basic symptoms-prediction list; CAARMS, comprehensive assessment of at risk mental states; CODGIS,
cognitive disturbances; DST, digit symbol test; EEG, electroencephalogram; ERP, event-related potentials; GAF: global assessment of functioning; HRSD, Hamilton Rating; Scale for
Depression; K-FTDS, Kiddie-Formal Thought Disorder Scale; LASSO, least absolute shrinkage and selection operator; MWT, Mehrfachwahl- Wortschatz test; NPV, negative predictive
value; PAS, Premorbid Adjustment Scale; PPV, predictive positive value; RAVLT-DR, Rey Auditory Verbal Learning-delayed recall;
RAVLT-Ret, Rey Auditory Verbal Learning-retention; SANS, Scale for Assessment of Negative Symptoms; SCPS, Strauss and Carpenter Prognostic Scale, score; SD, standard deviation;
SE, sensitivity; SFS, social functioning scale; SP, specificity; SPD, Schizotypal Personality Disorder subscale of the International Personality Disorder Examination; SIPS, structured
interview for prodromal syndromes; SVM, support vector machine; TAP, Testbatterie zur Aufmerksamkeitspr̈fung; TMT, trail-making test; WISC-III, Wechsler Intelligence Scales for
Children 3rd ed. for participants ages 11 to 15; WAIS-III, Wechsler Adult Intelligence Scales, 3rd ed; FSIQ, Full Scale Intelligence Quotient; HRSD, Hamilton Rating Scale for Depression.
aCut-off scores for determining sensitivity, specificity, and accuracy values were derived from the receiver operating characteristic curve.
bThe Youden Index (maximal value for sensitivity + specificity − 1) was 0.24 with the optimal cut point of a score of 3 for baseline disorganized communication.
cThis model included 58 (of 61) CHR subjects.le 223
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functions underlying these results particularly involved the
prefrontal perisylvian and subcortical brain structures and the
second (52) found that the predictor's decision function involved
grey matter volume alterations in prefrontal, perisylvian, and
subcortical structures, supporting the idea of the existence of a
cross-center neuroanatomical signature of emerging psychosis
enabling individualized risk staging across different high-risk
populations. Finally, another study (51) developed a multivariate
neuroanatomical pattern classification on the structural
magnetic resonance imaging data of individuals, in order to
help predicting transition to psychosis.
The highest PPV of 83% was reached using the predictive
variable of the grey matter volumes (grey matter volume
alterations in prefrontal, perisylvian, and subcortical
structures), with a SE of 76%, SP of 85%, and NPV of 78%
(52). This review has been internally validated. However, the
study sample was 66 subjects, constituting a rather small sample.
Globally, five of these studies (47, 49–52) were cross validated
and two were not (46, 48).
The worst PPV (77.8%) resulted from a predictive model
including MRI-based biomarkers. This predictive model yielded
an SE of 81%, SP of 87.5%, and NPV of 89.5% (50).
Neurocognitive Predictive Models
Five studies have analyzed the prognostic accuracy of cognitive
predictive models (Table 2). These studies have provided
measurements of IQ (41, 42, 55), verbal memory (54, 55),
attention (42), speech perception (53), executive functioning
(54), and processing speed (54, 55).
One of the studies (41) showed that low IQ was the single
neurocognitive parameter that discriminated patients at ultra-high
risk converted to psychosis from individuals who did not. The
severity of attenuated positive symptoms was the only significant
predictor of a transition to psychosis and disorganized symptoms
were highly predictive of functional outcome.
Another study (42) showed that best transition predictors
were selected APS (suspiciousness), negative symptoms
(anhedonia/asociality), and cognitive deficits (reduced speed of
information processing). Prediction of transitions could be
enhanced by a stronger weighting of certain early symptoms
and by inserting neurocognitive tests into a stepwise risk
assessment. Therefore, this study uses neurocognition in
addition to clinical parameters for predicting transition to
psychosis. Hoffman and colleagues (53) highlighted that
elevated LSI (length of speech illusion) scores indicated
increased risk of transition to psychotic disorders when
individual participating to the study were not taking
olanzapine. A further study (54) has demonstrated that
patients at risk of transition to psychosis could be identified on
an individual basis by evaluating neurocognitive test batteries
using multivariate pattern recognition. In another study (55)
several cognitive domains were identified as indicators of
vulnerability to psychosis. In addition, the results of the article
suggest that subtle deficits in verbal abilities (working and long-Frontiers in Psychiatry | www.frontiersin.org 9term memory, executive and intellectual functions) and
decreased speed of processing may help to predict transition
to psychosis.
Considering verbal and executive functioning in the
predictive model (neuropsychological functions were assessed
with a cross-domain neuropsychological test battery comprising
nine standardized tests that evaluated premorbid verbal IQ,
processing speed, working memory, verbal learning and
memory, executive functions, and verbal fluency), the highest
PPV of 83% could be obtained with a value of SE equal to 75%,
SP equal to 80%, and NPV equal to 71% (54). This model is the
only one that has been validated in this domain, with an internal
validation. However, the sample of the study is quite small,
resulting in 35 subjects. The worst PPV of 57% was achieved by
using a model including verbal IQ and attention (42). This model
yielded an SE of 80%, SP of 59%, and NPV of 83% (42).
Environmental Predictive Models
The prognostic accuracy of environmental predictive models was
evaluated in five papers (Table 2). These models have taken into
consideration substance abuse (36, 58), unemployment (56),
urbanity (57), social-sexual aspects (57), and social
maladjustments (43, 57).
Two studies analyzed substance abuse (36, 58). Buchy et al.
(58) and demonstrated that low use of alcohol contributed to the
prediction of psychosis. This study has also highlighted that
prediction algorithms including associations of additional
baseline variables known to be associated with psychotic
transition increase predictive power compared with substance
use alone. Cannon et al. (36) found that different features
contributed to the prediction of psychosis, including clinical
features and a history of substance abuse (alcohol, hypnotics,
cannabis, amphetamines, opiates, cocaine, hallucinogens):
predictive power was enhanced when prediction algorithms
combining two or three of these variables were developed.
Tarbox et al. (43) identified that early adolescent social
maladjustment and baseline suspiciousness together
demonstrated moderate positive predictive power (59%) and
high specificity (92.1%) in predicting transition to psychosis. A
study (57) has identified urbanicity, social–sexual aspects, and
social–personal adjustment as predictors of transition
to psychosis.
Another study (56) showed that unemployment at the first
contact with the prodromal service may be a risk factor for the
development of a psychotic episode.
The best predictive model was obtained in a study
conducted on 72 subjects, with values of PPV, SE, SP, and
NPV of 63%, 63%, 88%, and 88%, respectively (57). Measures
of urbanity, social-sexual aspects, and social and personal
adjustment were significant predictors (P < .001). The worst
PPV of 26% was achieved by using a model evaluating alcohol
use (“yes/no”). This model yielded an SE of 69%, SP of 81%,
and NPV of 90% (58).
There are no predicting models evaluating environmental
factors that have been validated.March 2020 | Volume 11 | Article 223
Montemagni et al. Psychosis in High-Risk PatientsCombinations of Predictive Models
Eighteen studies (36, 41–44, 59–71) have evaluated prognostic
accuracy combining different predictive models across domains
(Table 2).
Some of these studies concentrated their efforts in develop
predict ive models combining symptomatology and
neurophysiology (59, 65, 69). The first study (59) combined
different predictive models, suggesting that predicting transition
to psychosis could be improved with a model including
premorbid adjustment and information-processing variables
(specifically parietal P300 amplitude) in a multistep algorithm
combining risk detection and stratification. A second study (65)
demonstrated that patients who develop psychosis showed
significantly more pathological EEG abnormalities than
subjects who did not, located more frequently in temporal or
frontotemporal regions of the brain. The specificity of the
prediction of psychosis could be increased from 59 to 73% by
considering EEG pathology in addition to psychopathology
alone. Zimmermann and colleagues (69) have shown that
SANS score in combination with EEG power in four bands
(delta, theta, beta1, and beta2 bands), respectively, predicted
transition significantly in 13 individuals with later transition
to psychosis.
Other research studied predictive models focusing on
symptomatology and functioning (44, 61, 68, 70, 71). A
prediction model was developed including positive symptoms,
bizarre thinking, sleep disturbances, a schizotypal disorder, level
of functioning in the past year, and years of education (44).
Another study (61) developed a final predictor model, with a
positive predictive validity of 81.8%, consisted of four variables:
disorganized communication, suspiciousness, verbal memory
deficits, and decline in social functioning during follow-up. A
study (68) found three variables associated with transition to
psychosis: high unusual thought content scores; low functioning;
and having genetic risk with functional decline. Using a
combination of two out of three of these features, the
predictive validity of determining whether an individual
develops psychosis was improved, although using this method
the probability of a person not developing psychotic disorder is
still quite high at 35%. A study (70) yielded a method of
psychosis prediction at 12 months, identifying the following as
predictors: poor functioning, long duration of symptoms, high
levels of depression, and reduced attention. A combination of
family history of psychosis, a recent significant decrease in
functioning and recent experience of subthreshold psychotic
symptoms was also predictive of psychosis. A study (71)
developed a strategy for predicting transition to psychosis,
within a relatively brief follow-up period (12 months),
combining some highly significant predictors of psychosis:
long duration of prodromal symptoms, poor functioning at
intake, low-grade psychotic symptoms, depression, and
disorganization. A study (67) has developed a predictive model
focusing on individuals functioning and stigma. Specifically, this
study (67) showed that more perceived stigma stress at baseline
predicted transition to schizophrenia after adjusting for age,
gender, symptoms (positive and negative symptoms), andFrontiers in Psychiatry | www.frontiersin.org 10functioning. Other studies concentrate on cognitive deficits
and symptomatology (41, 42, 60, 62, 66). Another study (41)
has identified low IQ, the severity of attenuated positive
symptoms, and particularly disorganized symptoms as highly
predictive of functional outcome. A study (42) has identified as
the best transition predictors, selected APS (suspiciousness),
negative symptoms (anhedonia/asociality), and cognitive
deficits (reduced speed of information processing). A study
(60) demonstrated that prodromal patients (with APS) who
later developed psychosis had significantly lower verbal
memory scores at baseline, suggesting that verbal memory
deficits can represent an important risk marker of transition to
psychosis, possibly indicating the presence of a prefrontal-
hippocampal neurodevelopmental abnormality. A study (62)
found that the combination of a processing speed deficit (digit
symbol test) and at-risk criteria (APS plus subjective cognitive
disturbances) provides an optimized stratified risk assessment to
develop psychosis. A research (66) has studied movement
abnormalities and cognitive deficits demonstrating that
elevated dyskinetic movements in the upper-body region were
correlated with deficits in domains of verbal comprehension,
perceptual organization, and both immediate and delayed
auditory memory. Further, discriminant function analyses
indicated that baseline movement abnormalities and
neurocognitive deficits significantly classified subjects at risk to
develop psychosis (72.3%). Results support a common cortico-
striato-pallido-thalamic circuit irregularity, underlying both
movement abnormalities and cognitive deficits in individuals
at high risk for psychosis.
Another study focused on maladjustment of individuals at
high-risk to develop psychosis. Tarbox et al. (43) identified that
early adolescent social maladjustment and baseline
suspiciousness together demonstrated moderate positive
predictive power (59%) and high specificity (92.1%) in
predicting transition to psychosis. It uses also as predictor of
transition to psychosis the early adolescent social dysfunction.
Other research was carried out in the field of substance abuse.
Particularly, Cannon et al. (36) found that different features
contributed to the prediction of psychosis, including clinical
features and a history of substance abuse (alcohol, hypnotics,
cannabis, amphetamines, opiates, cocaine, hallucinogens):
predictive power was enhanced when prediction algorithms
combining two or three of these variables were developed.
Another interesting field that has been faced was about
predictive models combining biology and symptomatology. In
details, a study (63) developed a combined molecular/symptom-
based test. The authors described the development of a serum
biomarker test for the identification of individuals at risk of
transition to psychosis based on multiplex immunoassay
profiling analysis of 957 serum samples, identifying and
validating an optimal panel of 26 biomarkers that best
discriminated patients and controls. The performance
increased further incorporating the CAARMS (Comprehensive
Assessment of At-Risk Mental State) positive subscale symptom
scores into the model. Finally, attention was laid on emotion
recognition. Specifically, a study (64) showed how deficits inMarch 2020 | Volume 11 | Article 223
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psychosis. The authors, moreover, demonstrate that the best
classification model for schizophrenia onset included both face
emotion processing (facial emotion discrimination and
recognition) and negative symptoms. The highest PPV (86.3%)
was obtained in a study (66) that took into consideration
movement abnormalities, functional domains and neuro-
cognition, with values of SE of 76%, SP of 60%, and NPV of 43%.
The worst PPV of 49% was achieved using early adolescent
social maladjustment and baseline suspiciousness together as the
predictive variables, which produced an SE of 43%, SP of 78%,
and NPV of 72% (43).DISCUSSION
Although the field of risk prediction in mental health lags behind
other areas of medicine, some promising studies have been
conducted to begin to ascertain the operative combinations of
risk factors for a number of psychiatric disorders (72). These
models must be successfully replicated and validated in multiple
samples, external to the one used for the model development
phase. This often takes many years to be achieved. The use of risk
prediction models must be thoroughly evidence based, with
research demonstrating that the model is reliable and
applicable to the intended populations of individuals (73).
The prediction and prevention of psychotic disorders should
include a two-step approach: one step aimed at the identification of
individuals in CHR phase, the other aimed to further stratify risk so
that “indicated preventive interventions” can be given to patients in
the highest risk stratum in an even more targeted and intensive way.
The present review wants to extend the results of a recent review
of Schmidt et al. (28). Our review evaluated a total of 38 studies,
encompassing clinical, biological, neurocognitive, environmental, or
combinations of predictive models from various domains.
Four main findings should be highlighted.
First, while the highest PPVs in clinical (35), biological (51,
52), neurocognitive (54), and combined (66) predictive models
were quite high (all above 83), the highest PPV in environmental
predictive models was relatively low (63%) (57). This data could
be due to the heterogeneity in the environmental factors included
in the studies. Moreover, the examined environmental factors
were mostly those that have been related with psychotic
disorders, particularly substance abuse, urbanicity, and social
maladjustment, so that it is possible that their specificity in
detecting transition risk to psychosis of CHR is relatively poor, as
outlined by a recent meta-analysis (21).
Moreover, regarding the neurocognition, while many
previous studies have suggested that it is an important factor
in predicting transition to psychosis, there is significant
heterogeneity regarding the specific domains implicated:
measurements of IQ, verbal memory, attention, speech
perception, executive functioning, and processing speed (74, 75).
Second, none of the combined models showed a superiority
when compared with more parsimonious models (using only
neurocognitive, clinical, biological, or environmental factors).Frontiers in Psychiatry | www.frontiersin.org 11Thus, based on this data, it could be inferred that a strong PPV
can be reached making use of psychopathological or
neurocognitive data alone, therefore this approach should be
preferred to, i.e., extensive neuroimaging batteries. However, a
study (28) estimating the theoretical PPV of a sequential three-
stage testing (that contained various combinations of three models
predicting transition to psychosis, eg, electroencephalography/
clinical, images taken from MRI, and blood indicators) following
the initial CHR assessment, has shown that the highest value of PPV
was obtained when using in sequence a combined model (clinical +
EEG) and two biological models (structural MRI and blood
indicators). Particularly, PPV reached a value of 98% for subjects
with three positive tests, 71–82% for subjects with two positive
complementary tests, 12%–21% for subjects with one positive
complementary test, and 1% for subjects without any positive
tests. This study could indicate that testing in sequence CHR
individuals with models of prediction psychosis onset across
multiple domains could substantially enhance psychosis
prediction after the initial CHR assessment. Thus, multistage
sequential testing enables individual risk stratification of CHR
subjects to be made and improve prediction of transition to
psychosis. Third, it should be highlighted that only a few studies
have tried to replicate directly each other's risk algorithms.
Consequently, most published predictive performance estimates
are likely to be considerably overoptimistic. Only ten studies have
used a strict prognostic accuracy method matching appropriate
predictive models provided of internal validation. Some of the
studies presented an “apparent validation”, obtained on sample
used to develop model, leading to strongly overoptimistic results.
The majority part of the studies lacked sufficient details to precisely
apply the model in a new dataset and this can be partly explained by
the fact that there are no models externally validated.
In order to create rigorous risk prediction models, validation
is one of the most important elements. A useful prediction
model should give accurate estimates of risk, that can be used
from the physicians to help them in clinical management and
decision making. Moreover, this model should have a core role
in predict individuals' outcome and cost-effectiveness of care.
There is a substantial difference between models with internal
and external validation. When new individuals were subjected
to predictive model provided of internally validation, the
performance is was lower than the one observed in the
sample used to develop the model (76).
Fourth, our review found that poor conduct and reporting
were quite common in both predictor finding and model
developed studies. The results of our review highlight that
one of the biggest limitations is that most of the studies were
based on small sample sizes and number of events (particularly
patients with transitions to psychosis) relative to the number of
evaluated predictor variables. Small number of evaluated
predictor variables ratios enhance the risk of overestimating
the performance of the model, if it is developed and assessed in
the same sample. When sample sizes are small, as is it
frequently occurs in the field of prediction of psychosis
research, their performance advantage resulting from the
increased ability to capture the true underlying relationshipMarch 2020 | Volume 11 | Article 223
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compensate for the increased risk to overestimate.
Prediction in psychiatry needs to be considered a core aspect
for testing hypotheses regarding clinically relevant issues (77).
However, there are different problems that have to be faced
before develop risk prediction models in psychiatry: one of
them is the lack of availability of biological markers of illness;
another is the idea that a particular discrimination value (e.g.,
an AUC threshold of 0.80) is required before clinical adoption.
Indeed, in most prediction algorithms, including those
regarding the Framingham risk score (FRS), the AUC often
ranges from 0.75 to 0.80 (78).
Nevertheless, it's clear that a risk prediction model is useful
only if early and preventive intervention are available and
effective to prevent individual at high risk in developing
disease. The use of validated risk prediction algorithms,
despite being available, has delayed in primary care (79). If
effective predictive models were designed, all the efforts should
be done to make them useful and suitable for clinicians. In fact,
quantification of validated prediction model impact in clinical
care should be the target to be reached for implementation of
these models. Though, impact studies are even less frequently
performed than validation studies, as it can be elicited from
literature (80).
The research about risk prediction models should progress
together with the development of preventive interventions, i.e.,
long-chain w-3 polyunsaturated fatty acids (PUFAs). Although
w-3 PUFAs treatment is attractive for prevention from a
pathophysiologic perspective, preventive efficacy of w-3
PUFAs for psychosis had been demonstrated in one single-
site randomized, double-blind, placebo controlled trial which
has compared w-3 PUFAs with placebo (81), and later
confirmed in a naturalistic, long-term follow-up (82).
However, two large replication trials, the NEURAPRO trial
(83) and the NAPLS-2 trial (84), did not confirm the hypothesis
that w-3PUFAs may be helpful to prevent psychosis in CHR
individuals. The authors have hypothesized that such
discrepancies might be explained by different overall
transition rates, and by a ceiling effect due to concomitant
antidepressant treatment. Other trials are currently underway
to this end (Placebo-controlled Trial in Subjects at Ultra-high
Risk for Psychosis With Omega-3 Fatty Acids in Europe,
PURPOSE, NCT02597439). The efficacy of w-3PUFAs in sub-
groups of patients should also be investigated—for example, in
those with aberrant membrane fatty acid levels or
inflammatory markers
However, until now, recent meta-analyses have not found
robust evidence to favor specific preventive interventions, as
confirmed by a recent umbrella review (85), i.e. a review of
seven meta-analyses in the field of preventive interventions for
psychosis in CHR individuals.
Several methodological limitations of our systematic,
qualitative review must be acknowledged. First, we excluded
articles published in languages other than English. Second,
given the relative scarcity of research on this topic to date,Frontiers in Psychiatry | www.frontiersin.org 12and the variability across studies, we were not able to conduct a
quantitative systematic review or meta-analysis. Meta-analytic
results would be useful to provide important information
regarding common predictors and the predictive power of
existing models, but these are infeasible at present given the
very limited state of research in this neglected area of clinical
psychiatry. Third, combining the three CHR subgroups,
populations may confound predictors and have an impact on
the overall conversion rates (86) and, therefore, contribute to
inconsistencies across sites. As an example, if compared with
individuals at genetic high risk, people with intermittent
psychosis are more severely impaired and develop more
frequently acute psychosis (86). Therefore, extrapolating from
the whole high-risk category its three fundamental subgroups,
it is likely that more accurate predictors may be detected (61).
In conclusion, our systematic review revealed that poor
methods and reporting are very common in prediction of
psychosis research. In line with what has been reported
above, measures of discrimination and calibration of risk
prediction models have been reasonable. Most of the studies
are based on small samples, did not perform internal or external
cross-validation, and used poor model development strategies,
and this is the reason why most published models are probably
overestimated and their reported predictive accuracy is likely to
be overoptimistic. Therefore, the science of risk prediction
models in psychiatry is at the beginning, and this is clearly
evident looking at the numerous limitations that these studies
revealed. However, research on validation must be done. To
make these models useful in clinical practice, predictors must
be easily available and assessable, and people at high risk must
have access to preventive intervention, that could be considered
effective and with a minimal risk of side effects. As such, further
research must be conducted to create and improve efficient but
also focused preventive interventions. As for psychotic
disorders, research is growing up, especially toward the
direction of the risk prediction and risk stratification. The
research must go forward and our goal must be to make
effective prediction and prevention possible.AUTHOR CONTRIBUTIONS
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